[Development of novel immune therapies for solid tumors: phase I clinical trials in a single institute].
Yasuki
Y
Hijikata
Mutsunori
M
Murahashi-Iga
Toshihiko
T
Okazaki
Yoshihiro
Y
Tanaka
Kosuke
K
Odaira
Shinji
S
Okano
Terumasa
T
Hisano
Atsushi
A
Takahashi
Tomotoshi
T
Marumoto
Hiroyuki
H
Inoue
Kenzaburo
K
Tani
D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines; D017321:Clinical Trials, Phase I as Topic; D003520:Cyclophosphamide; D004268:DNA-Binding Proteins / Q000276:immunology / Q000627:therapeutic use; D006801:Humans; D007108:Immune Tolerance; D007166:Immunosuppressive Agents; D007167:Immunotherapy / Q000379:methods*; D016219:Immunotherapy, Adoptive; D009369:Neoplasms / Q000628:therapy*; D015513:Oncogene Proteins / Q000276:immunology / Q000627:therapeutic use; D010455:Peptides / Q000276:immunology*; D050378:T-Lymphocytes, Regulatory / Q000276:immunology; D044767:Ubiquitin-Protein Ligases
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004268:DNA-Binding Proteins; D007166:Immunosuppressive Agents; D015513:Oncogene Proteins; D010455:Peptides; D003520:Cyclophosphamide; C496945:RNF43 protein, human; D044767:Ubiquitin-Protein Ligases